Abstracts tagged "medication and rheumatoid arthritis (RA)"

Abstract Number: 3088 • 2016 ACR/ARHP Annual Meeting
Predictors of Non-Adherence with Anti-Rheumatic Medication in Rheumatoid Arthritis Patients: Data from a Rheumatoid Arthritis Cohort
Vandana Ahluwalia¹, Mohammad Movahedi^2,3, Emmanouil Rampakakis², Angela Cesta³, Xiuying Li³, John S. Sampalis⁴ and Claire Bombardier⁵, ¹Brampton Civic Hospital, Brampton, ON, Canada, ²JSS Medical Research, St-Laurent, QC, Canada, ³Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ⁴McGill University, Montreal, QC, Canada, ⁵University of Toronto, Toronto, ON, Canada
Background/Purpose: Despite the availability of safe and effective treatments and the establishment of treatment guidelines, real-world effectiveness remains suboptimal largely due to low patient adherence…
Abstract Number: 1559 • 2015 ACR/ARHP Annual Meeting
Clinical Characteristics and Medication Use Among Arab Patients with Rheumatoid Arthritis in Some Arab States
Karim Bayoumy¹, Soha Roger Dargham¹, Wessam Elhaq¹, Samar Al Emadi², Mohammed Hammoudeh², Basel Masri³, Hussein Halabi⁴, Humeira Badsha⁵, Imad Uthman⁶, Salah Mahdy², Robert Plenge⁷, Richa Saxena⁷, Marianthi Kapiri¹ and Thurayya Arayssi⁸, ¹Weill Cornell Medical College in Qatar, Doha, Qatar, ²Medicine, Hamad Medical Corporation, Doha, Qatar, ³Jordan Hospital, Amman, Jordan, ⁴Medicine, King Faisal Specialist Hospital and research center, Jeddah, Saudi Arabia, ⁵Al Biraa Arthritis and Bone Clinic, Dubai, United Arab Emirates, ⁶Internal Medicine, American University of Beirut, Beirut, Lebanon, ⁷The Broad Institute of MIT and Harvard, Program of Medical and Population Genetics, Cambridge, MA, ⁸Internal Medicine, Weill Cornell Medical College in Qatar, Doha, Qatar
Background/Purpose: Data on the clinical and genetic characteristics of Arab patients with Rheumatoid Arthritis (RA) is limited. Our aim is to report on the clinical…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].